Pharma

BPM Asks: What did three years of GLP-1 claims actually change?

Vicky Lee and Carey Wooton tell BPM what three years of claims experience changed in plan design

BPM Asks: What did three years of GLP-1 claims actually change?

Plan sponsors judge drug plans on cost, not health outcomes

Only 11% of sponsors grasp how their drug plan affects employee health, iA finds

Plan sponsors judge drug plans on cost, not health outcomes

Two-thirds with eczema struggle to find lasting treatment, survey finds

Landmarks across Canada will glow blue in November for Eczema Awareness Month

Two-thirds with eczema struggle to find lasting treatment, survey finds

Employer GLP-1 coverage doubles as generic semaglutide reaches Canada

Lockton Canada’s first market update hands plan sponsors a rare window to rein in drug spending

Employer GLP-1 coverage doubles as generic semaglutide reaches Canada

GLP-1 demand pulls a Canadian supplement maker into a Japanese takeover

Supplement deals hit US$14.6 billion through October as US regulators weigh new dietary ingredient rules

GLP-1 demand pulls a Canadian supplement maker into a Japanese takeover

Insurance coverage pushes GLP-1 uptake higher in Canada

Towards Healthcare values the global GLP-1 market rising to US$130 billion by 2035

Insurance coverage pushes GLP-1 uptake higher in Canada